Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26121979 | 0.86 | DRD2 (0.39) | DRD2DRD3GRIN1GRIN2BIDH1 | |
| SCHEMBL16595227 | 0.86 | DRD2 (0.41) | DRD2DRD3GRIN1GRIN2BIDH1 | |
| SCHEMBL22148381 | 0.83 | DRD2 (0.52) | DRD2DRD3GRIN1GRIN2BHDAC1 | |
| SCHEMBL12891728 | 0.75 | DRD2 (0.55) | DRD2DRD3GRIN1GRIN2BHDAC1 | |
| SCHEMBL14819902 | 0.75 | DRD2 (0.51) | DRD2DRD3GRIN1GRIN2BHDAC1 | |
| SCHEMBL8267166 | 0.75 | DRD2 (0.55) | DRD2DRD3GRIN1GRIN2BHDAC1 | |
| SCHEMBL1266027 | 0.75 | PLAU (0.55) | DRD2DRD3GRIN1GRIN2B | |
| SCHEMBL22791667 | 0.75 | DRD2 (0.51) | DRD2DRD3GRIN1GRIN2BHDAC1 | |
| SCHEMBL12891735 | 0.75 | DRD2 (0.55) | DRD2DRD3GRIN1GRIN2BHDAC1 | |
| SCHEMBL5051400 | 0.75 | PLAU (0.55) | DRD2DRD3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-208238347-U | Novel constant temperature is freezing device | 海门海康生物医药科技有限公司 | 2018-12-14 | — | — | CN | disclosed |
| CN-101309690-A | Chemokine receptor binding compounds | ANORMED INC (CA) | 2008-11-19 | — | — | CN | disclosed |
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | DRD2 1758/4885DRD3 1424/4885GRIN1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.